Navigation Links
CXCR4: A new drug target in lung cancer
Date:4/29/2010

Geneva, 29 April 2010 -- Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

CXCR4 is a receptor that is found on the surface of many different cell types in the body. It plays a role in immune system signaling between cells.

In cancer, evidence that CXCR4 is involved in the growth of tumors and their spreading throughout the body (metastasis) has been growing in recent years. For example, researchers have shown in studies in mice that blocking the action of CXCR4 inhibits metastasis. But its precise role in determining outcome and metastatic tendency, especially in lung cancer, is incompletely investigated.

Dr Gwyn Bebb and colleagues from the Tom Baker Cancer Centre in Calgary, Canada set out to explore whether patients whose tumors expressed high levels of the receptor had a worse prognosis than other lung cancer patients.

They studied tumor samples from 103 patients from the Glans-Look lung cancer database who were diagnosed with stage IV non-small-cell lung cancer (cancer which had already spread to other parts of the body) between 2003 and 2006. They found that 10.7% of the tumors over-expressed CXCR4. Those over-expressers had a significantly worse clinical outcome, with a median overall survival of 2.7 months, compared to 6.1 months among low-expressers.

If confirmed in an expanded series of 170 patients from the Glans-Look database, these results will suggest that new strategies to block CXCR4 should be tested in patients whose cancers over-express the molecule, the researchers say.

"I am quite excited about the possibility of using CXCR4 as a therapeutic target, but we need to learn more about its role in each specific malignancy," Dr Bebb said.

This possibility is especially promising because CXCR4 has been well studied in the context of HIV, where it is known to be a portal for the virus's entry into immune system cells. Drugs that block CXCR4 have already been developed for HIV/AIDS patients, and Dr Bebb's group thinks these drugs could quickly and easily be tested in the cancer setting.

"This is an exciting possibility," Dr Bebb said. "It seems very likely that a better understanding of the role of CXCR4 in lung cancer will lead to new treatment strategies and might allow us to meaningfully improve treatment for some lung cancer patients in the very near future."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Sundial Creations Announces the Debut of SheaMoisture Organic Hair Care Exclusively at Target
2. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
3. Global Summit on International Breast Health Targets Breast Health Improvements in Developing Countries, June 9-11, 2010, in Chicago
4. FDA Targets Safety Problems With Infusion Drug Pumps
5. Gene-Targeted Therapy Might Help Prevent Paralysis
6. Team finds promising new drug target for Alzheimers disease
7. Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building
8. New targeted therapy effective in treating advanced prostate cancer
9. Targeting the blood-brain barrier may delay progression of Alzheimers disease
10. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
11. New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... York (PRWEB) , ... August ... ... LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider ... has entered into a definitive agreement to purchase Unitrans International Corporation, a ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... launch of this summer’s edition of “Vision & Hearing,” advocating for active, healthy ... campaign focuses on resources available for individuals with hearing impairments and shares the ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, Eppendorf ... they will present the line of epMotion automated liquid handling system. This automated ... automate everyday pipetting tasks. , Ideal for scientists and lab technicians with no ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a ... throughout the greater DC region, is inaugurating a “New Leash On Life” charity ... and training them to be companions for veterans in need. , The Semper ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a ... in east Texas, is launching a regional charity effort to provide publicity assistance ... the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... 30, 2017.  The Company reported second quarter net sales ... prior year period, and an increase of 2.1% on ... of contribution from the LDR Holding Corporation acquisition, second ... of 2016, or 0.3% on a constant currency basis. ...
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... BEACH, Fla. , July 26, 2017 ... of enrollment of our clinical trial evaluating Altemia TM ... Cell Anemia (SCA) and Sickle Cell Disease (SCD). The ... to evaluate the efficacy and safety of Altemia TM ... trial is conducted under US IND 125274. ...
Breaking Medicine Technology: